Therapeutic Effect Of Nigella Sativa Oil On Different Clinical And Biochemical Parameters In Metabolic Syndrome

Size: px
Start display at page:

Download "Therapeutic Effect Of Nigella Sativa Oil On Different Clinical And Biochemical Parameters In Metabolic Syndrome"

Transcription

1 ISPUB.COM The Internet Journal of Pharmacology Volume 5 Number 2 Therapeutic Effect Of Nigella Sativa Oil On Different Clinical And Biochemical Parameters In Metabolic A Najmi, S Haque, R Khan, M Nasiruddin Citation A Najmi, S Haque, R Khan, M Nasiruddin. Therapeutic Effect Of Nigella Sativa Oil On Different Clinical And Biochemical Parameters In Metabolic. The Internet Journal of Pharmacology Volume 5 Number 2. Abstract Introduction: The seeds of Nigella sativa plant have been used to promote health and fight disease for centuries especially in the Middle East and Southeast Asia. This plant has been a great focus of research. This clinical study was undertaken to know the adjuvant effect of Nigella sativa oil on various clinical and biochemical parameters of Insulin resistance syndrome. Methodology: This prospective randomized control study was conducted at the tertiary health care centre of north India. After final diagnosis and considering inclusion and exclusion criteria one hundred and sixty one patients were enrolled in this study. Informed and written consent was taken from all the patients enrolled. Approval from institutional ethical committee was taken. Patients were divided into two groups. In-group I (standard group) patients were advised atorvastatin 10 mg once a day, metformin 500 mg twice a day, atenolol 50 mg once a day, amlodipine 5 mg once a day for a period of six weeks. In group II (Nigella sativa) group, patients were advised the above standard medication plus Nigella sativa oil 2.5 twice daily for a period of six weeks. Blood sugar both fasting and postprandial, fasting lipid profile and different parameters of obesity were recorded before therapy and after completion of therapy. Result: The abovementioned methodology was followed and it was found that the difference of percentage improvement in group II was significant with reference to low density lipoprotein, high density lipoprotein and fasting blood glucose (p<.05). Conclusion: Nigella sativa oil was found to be effective as add on therapy in patients of insulin resistance syndrome. Nigella sativa oil has a significant activity in diabetic and dyslipidemic patients. INTRODUCTION The National Cholesterol Education Program's Adult Treatment Panel III report (ATP III) identified the metabolic syndrome as a multiplex risk factor for cardiovascular disease (CVD) that is deserving of more clinical attention. The etiology, prevention and treatment of the metabolic syndrome are currently the focus of intense research activities. As public health epidemics go, metabolic syndrome does not seem to pack the punch of more sharply defined health threats, such as lung cancer or heart disease. But statistics expose some harsh realities. According to a 2002 report from the centre for disease control and prevention, about 22% of United States adults have metabolic syndrome. Expert believe that the report, based on data collected between 1988 and 1994 underestimate the current number of persons who have metabolic syndrome. Alternative medicine has opened new door for the treatment of cardiometabolic disorders which has attained epidemic proportion throughout the world. Nigella sativa seed, used for centuries for medicinal and culinary purposes and reported to possess a number of pharmacological properties, including antioxidant, anti-inflammatory, hypoglycemic, antihypertensive and antihyperlipidemic properties 1. But no study had been done previously in patients of metabolic syndrome. Hence it was considered worthwhile to study the adjuvant effect of Nigella sativa oil on various clinical and biochemical parameters in patients of Metabolic. The seeds of Nigella sativa plant have been used to promote health and fight disease for centuries especially in the Middle East and Southeast Asia. In South Asia, it is called Kalonji, its Arabic name is Habat-ul-Sauda and its English 1 of 11

2 name is Black cumin..the plant is widely grown in different parts of the world and is an annual herb cultivated in India. As an oriental spice, Nigella sativa has long been used as a natural remedy for the treatment of many acute as well as chronic diseases. This plant has been a great focus of research and has several traditional uses and consequently has been extensively studied for its chemical constituents and biological activities. Figure 1 Figure 1: Seeds of Nigella sativa plant >88 cms for females 2. Serum triglyceride > 150 mg % 3. Serum HDL <50 mg % 4. Blood pressure > 140/90 mm Hg 5. Fasting blood sugar > 110 mg % To diagnose a patient as a case of metabolic syndrome at least 3 or > 3 criteria should be present. EXCLUSION CRITERIA Pregnancy Type I diabetes mellitus Acute coronary syndromes and cerebrovascular accidents 4. Impaired liver function test 5. Patients of chronic renal disease 6. Familial dyslipidemia Advices about dietary and lifestyle changes were given to both Nigella sativa and standard groups. Dietary advice as recommended by NCEP was given. Eat low fat, low cholesterol foods Use low fat cooking methods e.g. Use nonstick pans, barbeque, roast, boil. MATERIAL AND METHODS After final diagnosis and considering inclusion and exclusion criteria patients were enrolled in this prospective study. Ethical Issues: Approval from institutional ethical committee was taken. Informed and Written Consent: The participants were informed of all possible expected benefits and possible harm ensuing from the study. Written consent was obtained from the study subjects. Study Design: Randomized prospective controlled study INCLUSION CRITERIA: 1. Abdominal obesity: Waist circumference >102 cms for males 2 of 11 Avoid alcohol consumption. Eat more fruits, vegetables and whole grains. Exercise: Patients of both groups were advised to take a brisk 30 minutes walk for 5 days in a week on empty stomach or one hour after having a meal. Waist circumference measurement technique Place measuring tape, holding it parallel to floor, around abdomen at the level of the iliac crest. Hold tape snug but do not compress the skin. Measure circumference at the end of normal expiration. (Identification, evaluation and treatment of overweight and obesity in adults: the practical guide. Bethesda National Institute of Health 2000, NIH publication ).

3 Figure 2 Atorvastatin 10 mg once a day Figure 2: Waist circumference measurement technique (With courtesy from McGraw Hill companies, 2004) Metformin 500 mg twice a day Amlodipine 5 mg once a day Atenolol 50 mg once a day Aspirin 150 mg once a day STATISTICAL ANALYSIS Pre and post treatment mean ± standard deviation of each parameter was calculated for both groups. The data were analyzed statistically using unpaired t test between Group I (Standard) and Group II (Nigella sativa).all the statistic were done by using 13 th version of SPSS software. OBSERVATIONS AND RESULTS Specific investigations: Blood sugar both fasting and postprandial Renal function test Fasting lipid profile Urine for albumin Liver function tests Nigella sativa Oil Nigella sativa oil (Kalonji oil, Mohammedia products, Red Hills, Nampally, Hyderabad) was procured from local market at Aligarh. As per manufacturer's information, it was prepared by steam distillation at Hyderabad, A.P., and India STUDY GROUPS: Group I. (Standard): Patients who were kept on standard regimen Group II.(Nigella sativa): Patients who were kept on standard regimen plus Nigella sativa oil 2.5 ml twice daily per orally for a period of six weeks as an add on therapy Standard Treatment: Following drugs were prescribed as a standard treatment for various disorders. 3 of 11 The present study was conducted on newly detected patients of metabolic syndrome in J.N. Medical College A.M.U. Aligarh from October 2005 to March 2007.The study group comprised of 161 patients. There were 115 males and 46 females. The age group of the patients varied from 20 years to 70 years but majority of the patients were in years age group. These patients were diagnosed as having metabolic syndrome according to ATP III criteria. Distribution of patients according to parameters of ATP III definition: Maximum numbers of our patients were suffering from obesity (93.7 %%) followed by low serum HDL (87.5 %) followed by raised serum triglyceride (84.3 %) followed by fasting blood glucose > 110 mg % (63.7 %) followed by hypertension (62.5 %)

4 Figure 3 Figure 5 TABLE: Distribution of patients according to parameters of ATP III definition TABLE 1: Body mass index Figure 4 GRAPH 3. Distribution of metabolic syndrome patients according to ATP III criteria Abdominal circumference: According to ATP III criteria abdominal obesity is calculated by measuring waist circumference. The cut off points for males and females are > 102 cms and > 88 cms respectively. The presence of abdominal obesity is more highly correlated with the metabolic risk factors than is an elevated BMI. Abdominal girth was reduced in both the groups. More reduction was seen in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of abdominal circumference are listed in the following table. Figure 6 TABLE 2: Abdominal circumference Hip circumference: Hip circumference was reduced in both the groups. More reduction was seen in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of hip circumference are listed in the following table. Figure 7 TABLE 3. Hip circumference DIFFERENT CLINICAL AND BIOCHEMICAL PARAMETERS Body mass index (BMI): According to WHO clinical criteria for metabolic syndrome the cut off point for BMI is > 30 Kg / meter 2. There was improvement in BMI of both the groups.improvement was more in Nigella sativa group as compared to Standard group but the difference in improvement between two groups was not significant.mean ± S.D. of pre and post treatment values of BMI are listed in the following table. 4 of 11 Body weight: Body weights were reduced in both the groups. The improvement was more in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of body weight are listed in the following table.

5 Figure 8 Figure 11 TABLE 4: Body weight TABLE 7: Diastolic blood pressure Waist hip ratio: According to WHO criteria of metabolic syndrome, the cut off point of waist hip ratio for males and females are respectively > 0.9 and >0.85 respectively. Waist hip ratio was improved in both the groups. Improvement was more in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of waist hip ratio are listed in the following table. Blood glucose: According to ATP III criteria the cut off point for fasting blood glucose is > 110 mg %. Cut points for several of these are less stringent than usually required to identify a categorical risk factor because multiple marginal risk factors can impart significantly increased risk for cardiovascular disease. Fasting blood glucose was reduced in both the groups but the reduction was significantly more (P value <.05) in Nigella sativa group. Postprandial blood glucose was reduced in both the groups. There was more improvement in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of fasting blood glucose are listed in the following table Figure 9 TABLE 5: Waist hip ratio Figure 12 TABLE 8: Fasting blood glucose Blood pressure: According to ATP III criteria for metabolic syndrome the cut off limit of blood pressure is > 130 /85 but in our study we had taken inclusion criteria of > 140 / 90 mm Hg because of convenience. Both systolic and diastolic blood pressure was reduced in both the groups. There was more reduction in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of systolic blood pressure are listed in the following table. Figure 13 TABLE 9: Postprandial blood glucose Figure 10 TABLE 6: Systolic blood pressure Total cholesterol (TC): Total cholesterol was reduced in both the groups. Reduction was more in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of TC are listed in the following table. 5 of 11

6 Figure 14 Figure 17 TABLE 10: Total cholesterol Table 13: LDL Triglyceride (TG): According to ATP III criteria dyslipidemia was defined as TG > 150 mg %. Triglyceride was reduced in both the groups. Reduction was more in Nigella sativa group but the difference between two groups was not significant. Mean ± S.D. of pre and post treatment values of TG are listed in the following table. Table below showing Post treatment mean ± S. D of standard and Nigella sativa group, t values and P values Figure 18 Table 14: Group statistics: Independent sample t test Figure 15 TABLE 11: Triglyceride High density lipoprotein (HDL): According to ATP III criteria the cut off point for HDL is < 40 mg % for males and < 50 mg % for females but in our study we had taken single cut off point of < 50 mg % both for males and females because of the purpose of convenience and feasibility. HDL was increased in both the above groups. Improvement in HDL was significant in Nigella sativa group (P<.05) as compared to standard group. Mean ± S.D. of pre and post treatment values of HDL are listed in the following table. Figure 16 Table 12: HDL Low density lipoprotein (LDL): According to ATP III guidelines dyslipidemia was defined as LDL > 130 mg %. LDL was reduced in both the groups but the reduction was significantly more (P<.05) in Nigella sativa group as compared to standard group. Mean ± S.D. of pre and post treatment values of LDL are listed in the following table. Number of patients in Group I = 82 Number of patients in Group II = 79 P value <.05 is taken as significant 6 of 11

7 DISCUSSION In our study we had taken five parameters for the measurement of obesity. They were body mass index, waist circumference, hip circumference, body weight and waist hip ratio. Advices about dietary and lifestyle changes as recommended by National Cholesterol Education Programme were given to both Nigella sativa and standard groups. In addition Nigella sativa oil 2.5 ml twice daily was added as add on therapy in Nigella sativa group. There was improvement in all the five abovementioned parameters in both groups but the improvement was more in Nigella sativa group as compared to standard group. Obesity is a major risk factor for type 2 diabetes and cardiovascular disease. It also is an important component of metabolic syndrome, although in a minority of obese persons, insulin resistance does not develop. Insulin resistance may also develop in persons classified as lean by body mass index (BMI) standards, who could thus be considered metabolically obese. Visceral adipose tissue has been proposed as the major site of fat deposition associated with the metabolic consequences of obesity 2. It is thought that visceral, or central, adiposity is the initial physical event that results in insulin resistance, by an increase in free fatty acid flux in portal and systemic circulations. No such clinical study had been done previously on antiobesity activity of Nigella sativa.antiobesity activity of Nigella sativa is being reported for the first time by us. The exact mechanism regarding antiobesity action is not known. In an animal study on rats 3 showed that petroleum ether extract of Nigella sativa had slight anorexic effect.the various constituents of Nigella sativa seeds for example lipase 4 may be responsible for its antiobesity action. It is the android obesity or apple shaped obesity that is associated with metabolic syndrome. The distribution of body fat is more important than the total quantity of fat in predicting the diabetes mellitus and associated macro vascular disease. The measurement of central obesity can be done by (1) measuring waist hip ratio, desired ratio, women < 0.8, men < 0.9 (2) measurement of waist: more than 88 cms in women and more than 102 cms in men, places them in high risk category for the development of metabolic syndrome. (ATP III guidelines 2001). Waist circumference has very crucial role in the detection and diagnosis of metabolic syndrome. Overweight and obesity are associated with insulin resistance and the metabolic syndrome. However, the presence of abdominal obesity is more highly correlated with the metabolic risk factors than is an elevated BMI. Therefore, the simple 7 of 11 measure of waist circumference is recommended to identify the body weight component of the metabolic syndrome. In our study for the treatment of hypertension we advised atenolol 50 mg plus amlodipine 5 mg in standard group.in Nigella sativa group we added Nigella sativa oil 2.5 ml twice daily. Reduction in both systolic and diastolic blood pressure was more in Nigella sativa group as compared to standard group. Our results were the same as reported previously in various studies. The various mechanism that were proposed for its antihypertensive effect of Nigella sativa were centrally acting antihypertensive agent, 5 calcium channel blocking activity 6 and its diuretic activity. 7 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure provides guidelines for intensive treatment of hypertension. Although use of thiazide diuretics and betablockers has been avoided in patients with glucose tolerance abnormalities, the safety and efficacy of such medications have been demonstrated in large clinical trials Drugs of these classes can be used in treatment of hypertension in patients with metabolic syndrome. We had taken a combination of atenolol and amlodipine because of certain advantages. Although Joint National Committee six (JNC VII) emphasize on single drug therapy, in practice a large majority of hypertensive ultimately require two or more drugs. In the Hypertension Optimal Treatment (HOT) study, a multicenter trial conducted in 26 countries, 70 % patients who achieved target blood pressure (BP) were being treated with two drugs. Even initial treatment of mild to moderate hypertension with a low dose combination is being advocated as an alternative strategy. Since BP is kept up by several interrelated factors, an attempt to block one of them tends to increase compensatory activity of the others. It is rational in such cases to combine drugs with different mechanism of actions for example drugs which increase plasma rennin activity diuretics, calcium channel blockers, Angiotensin converting enzyme inhibitors may be combined with drugs which lower plasma rennin activity beta blockers, clonidine, methyldopa. Atenolol is cardioselective beta one antagonist. Because of longer duration of action once daily dose is often sufficient. Side effects related to central nervous system action are less likely. No deleterious effect on lipid profile has been noted. Amlodipine is calcium channel blocker of dihydropyridine (DHP) group. It has complete but slow oral absorption. The early vasodilator side effects like palpitation, flushing, and postural dizziness are largely avoided. Diurnal fluctuation in blood level is small

8 and actions extend over the next morning. Its bioavailability is higher and more consistent. cholesterol 12. Further research is necessary to identify the mode of action of black cumin seeds. In our study for the treatment of elevated blood glucose we advised metformin 500 mg twice daily in standard group. In Nigella sativa group we added Nigella sativa oil 2.5 ml twice daily. Reduction in fasting and postprandial blood sugar in Nigella sativa group was more as compared to standard group. This reduction was statistically significant (P value < 0.05) in case of fasting blood glucose but not significant in case of postprandial blood glucose. We had taken metformin because of certain advantages. Metformin is a biguanide agent that lowers blood glucose primarily by decreasing hepatic glucose output and reducing insulin resistance. When used as monotherapy, metformin does not cause hypoglycemia and is thus termed an antihyperglycemic. The reported incidence of lactic acidosis during metformin treatment is less than 0.1 cases per thousand patient years and the mortality risk is even lower. Metformin does not promote weight gain and can reduce plasma triglyceride by 15 % to 20 %.Metformin is the only therapeutic agent that has been demonstrated to reduce macrovascular events in type 2 diabetes mellitus.(u.k. Prospective Diabetes Study Group, 1998). The Diabetes Prevention Program demonstrated the effectiveness of lifestyle change in persons with impaired fasting glucose, but metformin hydrochloride was also effective in delaying progression to overt diabetes in patients with impaired fasting glucose. 8 The same results were reported previously in various animal models of diabetes. The various mechanism proposed for its hypoglycemic activity were insulin sensitizing action 3 and stimulatory effect on beta cell function 9 Increase in High density lipoprotein (HDL) was more in Nigella sativa group as compared to standard group. This difference was significant (P value < 0.05). The same result was also reported previously 13 in rats. Reduction in Low density lipoprotein (LDL) cholesterol was significantly more (P value < 0.05) in Nigella sativa group as compared to standard group. LDL-c level may be decreased by increasing the production of LDL-c receptors. 14 Improvement in triglyceride (TG) was more in Nigella sativa group as compared to standard group but this difference was not significant. The same results were reported previously.treatment of the dyslipidemia of metabolic syndrome should involve nonpharmacologic interventions, including weight loss, exercise, and a low-fat diet. Reducing LDL-C levels with use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( statins ) is also appropriate for patients with metabolic syndrome. The ATP III guidelines recommend that LDL-C be the primary target of lipid-lowering therapy when a patient's triglyceride level is below 500 mg/dl. We had take atorvastatin because of certain advantages.statins are competitive inhibitors of 3hydroxy-3-methyl glutaryl coenzyme A (HMG Co A) reductase, which catalyzes an early, rate limiting step in cholesterol biosynthesis. The statins are the most effective and best tolerated agents for treating dyslipidemia (Goodman and Gilman's The pharmacological basis of therapeutics ) Statins have certain other cardioprotective benefits besides LDL lowering like improvement in endothelial function, 15 plaque stabilization 16, decreased the risk of coronary heart disease and levels of C- reactive proteins 17, inhibiting lipoprotein oxidation both in vivo and ex vivo 18, reduce platelet aggregation. Atorvastatin as a single agent may obviate the need for multiple drug therapy in high-risk patients 19. Atorvastatin is relatively more potent, cost effective and got the highest LDL cholesterol lowering efficacy at maximal daily dose of 80 mg.hepatic cholesterol synthesis is maximal between midnight and 2:00 A.M. Thus statins with half life of 4 hours or less (all but atorvastatin and rosuvastatin) should be taken in the evening or bed time. Atorvastatin has a long half life (18-24 hours), which allows administration of this statin at any time of the day. In our study for the treatment of dyslipidemia, we advised atorvastatin 10 mg once a day in standard group. In Nigella sativa group we added Nigella sativa oil 2.5 ml twice daily. Reduction in total cholesterol was more in Nigella sativa group (NS) as compared to standard group. Our results were the same as reported previously in various studies. Previous research workers 10 also reported the cholesterol lowering effect of Nigella sativa oil in animal studies. The presence of various unsaturated fatty acids like Arachidonic, eicosadienoic, linoleic, linolenic, oleic and almitoleic acid 11 may be responsible for the improvement of lipid profile. The various mechanisms were proposed for the lowering of cholesterol. The seeds may either inhibit de novo cholesterol synthesis or stimulate bile acid excretion. It is well-known that both effects would lead to a decrease in serum 8 of 11 In our study we advised low dose aspirin to the patients of both standard and Nigella sativa group. People with the

9 metabolic syndrome typically manifest elevations of fibrinogen, plasminogen activator inhibitor-1, and other coagulation factors. These abnormalities, however, are not routinely detected in clinical practice. For primary prevention, the only available long-term approach to counter their contribution to arterial thrombosis is low-dose aspirin or other antiplatelet agents. These agents, especially aspirin, are recommended in patients with established atherosclerotic cardiovascular disease (ASCVD) provided they are not contraindicated. Their efficacy in individuals with type 2 diabetes mellitus without ASCVD has not been established conclusively through clinical trials, although they are widely recommended in such individuals. In metabolic syndrome patients who are at moderately high risk for ASCVD events, aspirin prophylaxis is an attractive therapeutic option to lower vascular events. 20 CONCLUSION Among the five parameters for the ATP III definition of metabolic syndrome, significant beneficial effect of adding Nigella sativa oil was seen in case of high density lipoprotein followed by fasting blood glucose. Other parameters (blood pressure, serum triglyceride and waist circumference) were also improved in both the standard and Nigella sativa group. This improvement was more in Nigella sativa group as compared to standard group but this was not statistically significant. There was improvement in all the clinical and biochemical parameters in both the standard and Nigella sativa group. The different clinical parameters were systolic and diastolic blood pressure, body mass index, body weight, waist circumference, hip circumference and waist hip ratio. The various biochemical parameters were fasting and postprandial blood glucose, triglyceride, total cholesterol, high density lipoprotein, low density lipoprotein. Improvement was more in Nigella sativa group as compared to standard group for all the parameters. The improvement was statistically significant in case of fasting blood glucose, low density lipoprotein and high density lipoprotein. Our results are in conformity with earlier reports. However to the best of our knowledge antiobesity activity of Nigella sativa oil is being reported for the first time by us. The most important action of Nigella sativa that may be responsible for its beneficial effect in metabolic syndrome is its insulin sensitizing action. The various components of Nigella sativa that may be responsible for its beneficial effects in insulin resistance syndrome are thymoquinone, thymol, various unsaturated fatty acids, lipase and tannins. 9 of 11 Acknowledgements: The author is grateful to Dr.Mohd. Tariq Salman for his expert statistical guidance. The authors would also like to thanks Dr. Razi Ahmad and Dr.Kamal C.M for their guidance and support. References 1. Bamosa AO et al (1997): Effect of oral ingestion of Nigella sativa seeds in some blood parameters. Saudi Pharm J, 5(2-3): Wajchenberg BL Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.endocr Rev 2000; 21(6): Abdellatif Settaf, Aziz Elimadi, Yehiya Cherrah, et al, The petroleum ether extracts of Nigella sativa seeds exert insulin sensitizing and lipid lowering action in rats.journal.of Ethanopharmacology, 2004, Volume 94, Issue 2-3: Aylin Akova, Gulem Ustun, Activity and adsorption of lipase from Nigella sativa seeds, Biotechnology Letters, Volume 22, Page , Tahir KE, Ashour M. M. S., et al. (1993). The respiratory effects of the volatile oil of the Black Seed (Nigella sativa) in guinea pigs: Elucidation of the mechanism(s) of action. General Pharmacology 24(5): : Dep. Pharmacol., College Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. 6. Aqel, M. (1992a) The calcium antagonistic effect of the volatile oil of Nigella sativa seeds. Dirasat Series B Pure and Applied Sciences 19(1): Dep. Anat., Fac. Med., Anat. /Smooth Muscles, Univ. Aiwa, USA. 7. Zaoui, A., Cherrah, Y. et al. (2000). Diuretic and hypotensive effects of Nigella sativa on the spontaneously hypertensive rat. Therapie London. Mai Juin 55(3): : Laboratoire de Pharmacologie et Toxicologie, Faculte de Medecine et Pharmacie de Rabat, Universite Med V, Rabat, Morocco. 8. Knowler WC, Barrett Connor E, Fowler SE et al.reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.diabetes Prevention Programe Research group N Eng J Med 2002, 346(6): Meral, I., Z. Yener, T. Kahraman and N. Mert, Effect of Nigella sativa on glucose concentration, lipid peroxidation, anti-oxidant defense system and liver damage in experimentally-induced diabetic rabbits. J. Vet. Med. A. Physiol. Pathol. Clin. Med., 48: ). 10. Abdul Sattar, Allah Ditta, Muhammad Tayyib, Muhammad Ashraf.Estimation of serum lipids in albino Rats fed on palm oil and atherogenic diet and Nigella sativa. Pakistan Postgrad Med J Sep 2003; 14(3): El-Dakhakhny M (1963): Studies on chemical constitution of Egyptian N sativa L seeds II. The Essential oil. Planta Med, 11; Beynen, A.C., M.B. Katan and L.F.M. Van Zutphen, Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Adv.Lipid Res., 22: Amir Hamzo Dahri, Atta Muhammad Chandiol, Ali Akbar Rahoo Rafique Ahmed Memon, Effect of Nigella sativa on serum cholesterol of albino rats, (2001) Department of Pathology, Biochemistry and Medicine Peoples Medical College Nawabshah. 14. Chaudhary et al 1996 Nigella satival. Oil protects against induced hepatotoxicity and improves serum lipid profile in rats. Arzneimittel Forschung, 50: O'Driscoll, G.Greenand Taylor R.R. Simvastatin, an

10 HMG Co A reductase inhibitor, improve endothelial function within one month. Circulation, 1997, 95: Bustos C.,Hernandez Presa, et al. HMG CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis Am. Coll.Cardiol.1998, 32: Libby, P. Aikawa, Inflammation in atherosclerosis, Nature, 2002, 420: Hussein, O., Rosenblat, M. et al. (1997) Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to 10 of 11 platelets.br.j.clin. Pharmacol., 44: Nawrocki JW, Weiss SR, Davidson MH, Sprecher L, Schwartz SL, Lupien PJ, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995; 15: Pearson TA, Blair SN, et al (2002) AHA Guidelines for primary prevention of cardiovascular disease and stroke. American Heart association Science Advisory and Coordinating Committee. Circulation.106:

11 Author Information Ahmad Najmi, MBBS, MD Junior Resident III, Dept. Of Pharmacology, J.N.Medical College, Aligarh Muslim University Shahzad F. Haque, MBBS, MD Reader, Dept. Of Medicine, J.N.Medical College, Aligarh Muslim University Rahat Ali Khan, MBBS, MD Professor, Dept. Of Pharmacology, J.N.Medical College, Aligarh Muslim University Mohd Nasiruddin, MBBS, MD Lecturer, Dept. Of Pharmacology, J.N.Medical College, Aligarh Muslim University 11 of 11

IJPRD, 2011; Vol 4(1): March-2012 ( ) International Standard Serial Number

IJPRD, 2011; Vol 4(1): March-2012 ( ) International Standard Serial Number IJPRD, 2011; Vol 4(1): March-2012 (140-144) International Standard Serial Number 0974 9446 --------------------------------------------------------------------------------------------------------------------------------------------------

More information

SSRG International Journal of Medical Science (SSRG-IJMS) Volume 4 Issue 3 March 2017

SSRG International Journal of Medical Science (SSRG-IJMS) Volume 4 Issue 3 March 2017 Effect of Kalonji (N. Sativa) Seeds on Glycemic Control of Patients with Type-2 Diabetes *Shafi M. Shaafi 1, Harish Kulkarni 2 1 Associate Professor, Department of Biochemistry, Kannur Medical College

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

American Diabetes Association 2018 Guidelines Important Notable Points

American Diabetes Association 2018 Guidelines Important Notable Points American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating

More information

B. Patient has not reached the percentage reduction goal with statin therapy

B. Patient has not reached the percentage reduction goal with statin therapy Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients

More information

International Journal of Research and Development in Pharmacy and Life Sciences. Research Article

International Journal of Research and Development in Pharmacy and Life Sciences. Research Article International Journal of Research and Development in Pharmacy and Life Sciences Available online at http//www.ijrdpl.com February - March, 214, Vol. 3, No.2, pp 943-948 ISSN: 2278-238 Research Article

More information

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role

More information

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents

Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of

More information

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI

More information

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh "Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July

More information

http://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current

More information

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered

More information

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016 Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN 1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics

More information

Established Risk Factors for Coronary Heart Disease (CHD)

Established Risk Factors for Coronary Heart Disease (CHD) Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland

More information

Antihyperlipidemic Drugs

Antihyperlipidemic Drugs Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,

More information

Therapeutic effect of flavonoid rich extract of apricots on high-fat diet induced hyperlipidemia in rabbits

Therapeutic effect of flavonoid rich extract of apricots on high-fat diet induced hyperlipidemia in rabbits Therapeutic effect of flavonoid rich extract of apricots on high-fat diet induced hyperlipidemia in rabbits in rabbits TOOBA LATEEF Assistant Professor Department of Biochemistry Jinnah University for

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD

ANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed

More information

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Original Research Article A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Deepa Kalikavil Puthenveedu 1, Sundaraj

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

American Diabetes Association: Standards of Medical Care in Diabetes 2015

American Diabetes Association: Standards of Medical Care in Diabetes 2015 American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform

More information

Antihyperlipidemic Drugs

Antihyperlipidemic Drugs Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types

More information

The Paleolithic Diet. A Review

The Paleolithic Diet. A Review The Paleolithic Diet A Review by: Philip Rouchotas, MSc, ND Bolton Naturopathic Clinic 64 King St. W, Bolton, Ontario L7E 1C7 info@boltonnaturopathic.ca What is the Paleolithic Diet? Today s modern diet

More information

Diabetic Dyslipidemia

Diabetic Dyslipidemia Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century November 2, 2016 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

More information

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity

More information

Guidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals

Guidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals Guidelines for Integrated Management of Cardiovascular Diseases and Diabetes in Clinics and Ri-hospitals Ministry of Public Health DPR Korea January 2013 Rationale ncommunicable diseases such as cardiovascular

More information

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.

More information

Rick Fox M.A Health and Wellness Specialist

Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Rick Fox M.A Health and Wellness Specialist Metabolic Diseases Metabolism is the process your body uses to get or make energy from the food you eat. Food is made up of proteins, carbohydrates

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

year resident, Department of Medicine, B. J. Medical college, Ahmedabad.

year resident, Department of Medicine, B. J. Medical college, Ahmedabad. Clinical Study of Type 2 Diabetes Mellitus Patients with or without Cerebrovascular Feature and Its Correlation with Other Comorbidity / Diabetic Complication Vivek Sidhapura 1*, Bipin Amin 2, Amit Potulwar

More information

Metabolic Syndrome and Chronic Kidney Disease

Metabolic Syndrome and Chronic Kidney Disease Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference

More information

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010 Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS

METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS METABOLIC SYNDROME IN TYPE-2 DIABETES MELLITUS S.M. Sohail Ashraf 1, Faisal Ziauddin 2, Umar Jahangeer 3 ABSTRACT Objective: To find out the prevalence of metabolic syndrome in type-2 Diabetes Mellitus

More information

Hypertension and Hyperlipidemia. University of Illinois at Chicago College of Nursing

Hypertension and Hyperlipidemia. University of Illinois at Chicago College of Nursing Hypertension and Hyperlipidemia University of Illinois at Chicago College of Nursing 1 Learning Objectives 1. Provide a basic level of knowledge regarding hypertension and hyperlipidemia and care coordinators/

More information

Metformin Hydrochloride

Metformin Hydrochloride Metformin Hydrochloride 500 mg, 850 mg, 500 mg LA and 750 mg LA Tablet Description Informet is a preparation of metformin hydrochloride that belongs to a biguanide class of oral antidiabetic drugs. Metformin

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

Metabolic Syndrome.

Metabolic Syndrome. www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Common Diabetes-related Terms

Common Diabetes-related Terms Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes

More information

Diabetes and Heart Disease

Diabetes and Heart Disease Diabetes and Heart Disease Sarah Alexander, MD Assistant Professor of Medicine Division of Cardiology Rush University Medical Center 2/8/2017 Rush is a not-for-profit health care, education and research

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H. U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,

More information

APPENDIX 2F Management of Cholesterol

APPENDIX 2F Management of Cholesterol Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney

More information

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi

Hyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia

More information

CONTRIBUTING FACTORS FOR STROKE:

CONTRIBUTING FACTORS FOR STROKE: CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING

More information

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME

HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing

More information

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010

Cardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century October 4, 2010 Content Introduction The number 1 killer in America Some statistics

More information

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

More information

In 2001, the National Cholesterol Education Program

In 2001, the National Cholesterol Education Program At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

Natural Approaches to Cholesterol Deregulation

Natural Approaches to Cholesterol Deregulation Most of us have inherited certain physiological weaknesses that may require ongoing attention and as we get older certain issues tend to arise that need specific requirements. Cholesterol Imbalance and

More information

Chapter 18. Diet and Health

Chapter 18. Diet and Health Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in

More information

4/24/15. AHA/ACC 2013 Guideline Key Points

4/24/15. AHA/ACC 2013 Guideline Key Points Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement

More information

Case Study: Chris Arden. Peripheral Arterial Disease

Case Study: Chris Arden. Peripheral Arterial Disease Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she

More information

Management of Post-transplant hyperlipidemia

Management of Post-transplant hyperlipidemia Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and

More information

Session 21: Heart Health

Session 21: Heart Health Session 21: Heart Health Heart disease and stroke are the leading causes of death in the world for both men and women. People with pre-diabetes, diabetes, and/or the metabolic syndrome are at higher risk

More information

New ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC

New ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC New ES Guidelines on ardiovascular Disease Prevention in linical Practice Lipids Professor Željko Reiner, MD, PhD, FRP(Lond), FES, FA University Hospital enter Zagreb School of Medicine, University of

More information

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health

More information

THE SAME EFFECT WAS NOT FOUND WITH SPIRITS 3-5 DRINKS OF SPIRITS PER DAY WAS ASSOCIATED WITH INCREASED MORTALITY

THE SAME EFFECT WAS NOT FOUND WITH SPIRITS 3-5 DRINKS OF SPIRITS PER DAY WAS ASSOCIATED WITH INCREASED MORTALITY ALCOHOL NEGATIVE CORRELATION BETWEEN 1-2 DRINKS PER DAY AND THE INCIDENCE OF CARDIOVASCULAR DISEASE SOME HAVE SHOWN THAT EVEN 3-4 DRINKS PER DAY CAN BE BENEFICIAL - WHILE OTHERS HAVE FOUND IT TO BE HARMFUL

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

Original paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3

Original paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3 Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,

More information

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia ISPUB.COM The Internet Journal of Cardiovascular Research Volume 3 Number 1 Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia V Save, N Patil, G Rajadhyaksha Citation V Save,

More information

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI Hypertension, Hyperlipidemia and Obesity Mi-CCSI Objectives Review the prevalence of hypertension, hyperlipidemia and obesity Correlation of the 3 conditions Discuss why it is important to treat these

More information

The role of physical activity in the prevention and management of hypertension and obesity

The role of physical activity in the prevention and management of hypertension and obesity The 1 st World Congress on Controversies in Obesity, Diabetes and Hypertension (CODHy) Berlin, October 26-29 2005 The role of physical activity in the prevention and management of hypertension and obesity

More information

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL

More information

overweight you are part of it!... Healthier, fitter, safer... Seafarers Health Information Programme ICSW S.H.I.P.

overweight you are part of it!... Healthier, fitter, safer... Seafarers Health Information Programme ICSW S.H.I.P. overweight you are part of it!... Seafarers Health Information Programme Healthier, fitter, safer... S.H.I.P. ICSW BROCHUREA5_COR1.indd 1 24/08/2007 19:38:40 Overweight prevention, you are part of it!...

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C

More information

Drugs for Dyslipidemias

Drugs for Dyslipidemias Drugs for Dyslipidemias HMG CoA reductase inhibitors (statins): atorvastatin, lovastatin, pravastatin, simvastatin Bile acid-binding resins: cholestyramine, colestipol, colesevelam Fibric acid derivatives

More information

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)

The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division

More information

Updates in Cardiovascular Recommendations for Diabetic Patients

Updates in Cardiovascular Recommendations for Diabetic Patients Updates in Cardiovascular Recommendations for Diabetic Patients Chris Tawwater, Pharm.D., BCPS Clinical Pharmacist, Abilene Regional Medical Center Assistant Professor, Adult Medicine Division Pharmacotherapy

More information

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic

More information